FibroGen (NASDAQ:FGEN) Announces Earnings Results
FibroGen (NASDAQ:FGEN) Announces Earnings Results
FibroGen (NASDAQ:FGEN – Get Rating) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.16, Briefing.com reports. FibroGen had a negative net margin of 109.22% and a negative return on equity of 109.09%. The business had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same period in the prior year, the firm earned ($1.45) EPS. The business's revenue for the quarter was up 22.3% on a year-over-year basis.
FibroGen(纳斯达克:FDEN-GET Rating)周一发布了季度收益数据。据Briefing.com报道,这家生物制药公司公布了本季度每股收益(0.78美元),比普遍预期的(0.94美元)高出0.16美元。FibroGen的净利润率为负109.22%,净资产回报率为负109.09%。该业务本季度的收入为2981万美元,而普遍预期为3615万美元。去年同期,该公司每股收益为1.45美元。该业务当季营收同比增长22.3%。
FibroGen Stock Performance
FibroGen股票表现
Shares of FGEN stock opened at $14.12 on Wednesday. The company has a market cap of $1.32 billion, a PE ratio of -4.64 and a beta of 0.87. FibroGen has a fifty-two week low of $7.81 and a fifty-two week high of $16.91. The stock's fifty day moving average price is $11.53 and its two-hundred day moving average price is $11.99.
周三,fgen股票开盘报14.12美元。该公司市值13.2亿美元,市盈率为-4.64,贝塔系数为0.87。FibroGen的52周低点为7.81美元,52周高位为16.91美元。该股的50日移动均线价格为11.53美元,200日移动均线价格为11.99美元。
Hedge Funds Weigh In On FibroGen
对冲基金对FibroGen的看法
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in FibroGen by 3.5% during the first quarter. Vanguard Group Inc. now owns 9,349,957 shares of the biopharmaceutical company's stock valued at $112,387,000 after buying an additional 313,769 shares during the period. State Street Corp lifted its position in FibroGen by 9.3% during the first quarter. State Street Corp now owns 4,927,781 shares of the biopharmaceutical company's stock valued at $59,232,000 after acquiring an additional 420,828 shares during the last quarter. Federated Hermes Inc. increased its stake in shares of FibroGen by 84.1% in the first quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company's stock worth $28,799,000 after acquiring an additional 1,094,403 shares during the period. Dimensional Fund Advisors LP grew its position in shares of FibroGen by 204.5% in the first quarter. Dimensional Fund Advisors LP now owns 732,183 shares of the biopharmaceutical company's stock valued at $8,801,000 after purchasing an additional 491,722 shares during the period. Finally, Renaissance Technologies LLC raised its stake in FibroGen by 594.1% during the first quarter. Renaissance Technologies LLC now owns 687,900 shares of the biopharmaceutical company's stock worth $8,269,000 after purchasing an additional 588,800 shares during the period. Hedge funds and other institutional investors own 77.35% of the company's stock.
一些对冲基金和其他机构投资者最近调整了对该公司的持股。先锋集团(Vanguard Group Inc.)第一季度将其在FibroGen的头寸增加了3.5%。先锋集团现在持有这家生物制药公司9,349,957股股票,价值112,387,000美元,在此期间又购买了313,769股。道富集团在第一季度将其在FibroGen的头寸提高了9.3%。道富集团目前持有这家生物制药公司4,927,781股股票,价值59,232,000美元,此前该公司在上个季度额外收购了420,828股。联合爱马仕公司在第一季度增持了84.1%的FibroGen股票。联合爱马仕公司目前持有这家生物制药公司2,395,883股股票,价值28,799,000美元,在此期间又收购了1,094,403股。Dimensional Fund Advisors LP在第一季度将其在FibroGen的股票头寸增加了204.5%。Dimension Fund Advisors LP现在拥有这家生物制药公司732,183股票,价值8,801,000美元,在此期间又购买了491,722股票。最后,复兴科技有限责任公司在第一季度将其在FibroGen的持股增加了594.1%。复兴科技有限责任公司目前持有这家生物制药公司68.79万股股票,价值8,269,000美元,在此期间又购买了588,800股票。对冲基金和其他机构投资者持有该公司77.35%的股票。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
About FibroGen
关于FibroGen
(Get Rating)
(获取评级)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen,Inc.是一家生物制药公司,发现、开发和商业化治疗严重未得到满足的医疗需求的疗法。该公司正在开发一种口服低氧诱导因子Pro羟基酶小分子抑制剂roxadustat,该药已在美国、欧洲、中国和日本完成了治疗慢性肾脏疾病贫血的第三阶段临床开发,并在中国完成了治疗与骨髓增生异常综合征相关的贫血的第二/第三阶段临床开发。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- CVS and Walgreens Show Why Investment Objectives Matter
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
- 免费获取StockNews.com关于FibroGen的研究报告(Fgen)
- 3M、霍尼韦尔、通用电气在季度报告后收购吗?
- 这只国防股票的基本面和技术面都看涨
- 索菲金融股票终于准备好为投资者买单了吗?
- CVS和Walgreens展示为什么投资目标很重要
- 美敦力和直觉外科公司准备实现大增长吗?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对FibroGen和相关公司的最新新闻和分析师评级的每日简要摘要。